US flu season continues to decline, but hospitalizations up again
Influenza activity continues to drop in the United States even as rates of hospitalization for flu continue to climb, the Centers for Disease Control and Prevention (CDC) said today in its weekly update. The CDC also reported three flu-related deaths in kids.
Almost all key markers for flu activity dropped again in the week that ended Apr 18, the CDC said, indicating a waning season. The percentage of respiratory specimens that tested positive for influenza dropped substantially nationwide, to 7.6%, down from 9.6% the week before. The percentage varied widely by region, however, reaching as high as 16.9% in the Midwest.
The estimated proportion of outpatient visits for flulike illness was 1.4%, down from 1.8% and well below the 2.0% baseline level for the third straight week.
Flu activity was geographically widespread in the same three states as the week before: New York, Massachusetts, and Connecticut. Ten states reported regional activity, down from 14 the week before. All 50 states reported minimal flu activity, compared with 44 the week before.
The CDC reported 3 new flu-related pediatric deaths after none the previous week, bringing the total for the season to 128. The proportion of deaths from pneumonia and flu climbed a bit, to 6.7%, up from 6.5% but still below the epidemic threshold of 7.0%.
The cumulative hospitalization rate, however, climbed for yet another week, from 62.4 per 100,000 population to 63.6 per 100,000. And the rate in those 65 and older set yet another record since the CDC began recording that data in 2005-06. It rose from 308.0 to 313.8 per 100,000.
Influenza B continued its typical late-season surge, accounting for 88.2% of influenza viruses typed, up from 87.1% the week before.
Apr 24 CDC FluView update
Apr 24 CDC flu situation report
Trial shows Vietnam-made H5N1 vaccine safe, immunogenic
A Vietnam-made H5N1 influenza pandemic vaccine candidate proved safe and immunogenic in a phase 1 trial, Viet Nam News (VNS) reported today.
Of 75 people participating in the trial, 32 received a 15-microgram (mcg) dose of the vaccine, , 31 received a 7.5-mcg dose, and 12 received a placebo. The vaccine was produced by the Institute of Vaccines and Medical Biologicals of Viet Nam (IVAC).
The higher dose of the vaccine, called IVACFLU-H5N1, was shown to be immunogenic "according to standard testing methods," the story said. No serious local or systemic adverse events were noted in any of the volunteers.
"We confirm the readiness of IVACFLU-H5N1 to progress into phase 2 and 3 clinical trials," said Dr. Le Van Be, IVAC director.
The study was conducted by the HCM City Pasteur Institute. It was funded by the World Health Organization with a grant through the Biomedical Advanced Research and Development Authority (BARDA) of the US Department of Health and Human Services.
Apr 24 VNS story